Johnson & Johnson closed at $230.42, up 2.58% for the week, with buyers returning to defensive healthcare. A 12-month price target of $252.01 implies 9.37% upside, and the recommendation is buy with 90% confidence. The stock has risen strongly over the past year, though it pulled back after Q1 results. Q1 2026 showed revenue growth to $24.06 billion and adjusted EPS of $2.70, extending a multi-quarter beat streak. Innovative Medicine growth was supported by DARZALEX and TREMFYA, offsetting STELARA decline. The bull case targets $265.94, led by oncology products and new combination therapies, plus additional launches and a cell therapy facility. Risks include biosimilar erosion and other competitive pressures.
"The planned Orthopaedics business separation could unlock a sum-of-the-parts rerating north of $270. Insider buying reinforces this: R&D chief John Reed acquired 25,255 shares on May 1, 2026. The bear scenario lands at $215.11, a 6.64% drawdown. STELARA biosimilar erosion produced a 920 bp"
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]